AU2020228367A1 - Antigen binding proteins that bind BCMA - Google Patents

Antigen binding proteins that bind BCMA Download PDF

Info

Publication number
AU2020228367A1
AU2020228367A1 AU2020228367A AU2020228367A AU2020228367A1 AU 2020228367 A1 AU2020228367 A1 AU 2020228367A1 AU 2020228367 A AU2020228367 A AU 2020228367A AU 2020228367 A AU2020228367 A AU 2020228367A AU 2020228367 A1 AU2020228367 A1 AU 2020228367A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020228367A
Other languages
English (en)
Inventor
Xia Cao
Heyue Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivasor Inc
Original Assignee
Vivasor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivasor Inc filed Critical Vivasor Inc
Publication of AU2020228367A1 publication Critical patent/AU2020228367A1/en
Assigned to VIVASOR, INC. reassignment VIVASOR, INC. Request for Assignment Assignors: SORRENTO THERAPEUTICS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2020228367A 2019-02-26 2020-02-25 Antigen binding proteins that bind BCMA Abandoned AU2020228367A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810771P 2019-02-26 2019-02-26
US62/810,771 2019-02-26
US201962811431P 2019-02-27 2019-02-27
US62/811,431 2019-02-27
PCT/US2020/019763 WO2020176549A1 (en) 2019-02-26 2020-02-25 Antigen binding proteins that bind bcma

Publications (1)

Publication Number Publication Date
AU2020228367A1 true AU2020228367A1 (en) 2021-10-14

Family

ID=72238662

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020228367A Abandoned AU2020228367A1 (en) 2019-02-26 2020-02-25 Antigen binding proteins that bind BCMA

Country Status (12)

Country Link
US (1) US20210388097A1 (https=)
EP (1) EP3930852A4 (https=)
JP (1) JP7554759B2 (https=)
KR (1) KR20210133261A (https=)
CN (1) CN113874082B (https=)
AU (1) AU2020228367A1 (https=)
BR (1) BR112021016791A2 (https=)
CA (1) CA3130765A1 (https=)
IL (1) IL285813A (https=)
MX (1) MX2021010281A (https=)
SG (1) SG11202109163YA (https=)
WO (1) WO2020176549A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022546577A (ja) * 2019-09-05 2022-11-04 ソレント・セラピューティクス・インコーポレイテッド Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ）
MX2023007901A (es) 2020-12-31 2023-07-11 Sanofi Sa Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123.
US20240181073A1 (en) 2021-03-03 2024-06-06 Sorrento Therapeutics, Inc. Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
IL317227A (en) 2022-05-27 2025-01-01 Sanofi Sa Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering
US20240117062A1 (en) * 2022-05-27 2024-04-11 Sanofi Anti-bcma antibodies
CN119841951B (zh) * 2024-12-25 2025-10-14 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) 一种抗bcma抗体或其抗原结合片段及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2005016111A2 (en) * 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
ES2650224T3 (es) * 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
EA201590877A1 (ru) * 2012-11-13 2015-09-30 Ридженерон Фармасьютикалз, Инк. Антитела к прокинетициновым рецепторам (prokr) их применение
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
TW201632559A (zh) * 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
PL3988117T3 (pl) * 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
US10072088B2 (en) * 2015-08-17 2018-09-11 Janssen Pharmaceutica, Nv Anti-BCMA antibodies and uses thereof
US20170233484A1 (en) * 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
US10988546B2 (en) * 2017-08-01 2021-04-27 Medimmune, Llc BCMA monoclonal antibody-drug conjugate
US20200224160A1 (en) * 2018-02-27 2020-07-16 Sorrento Therapeutics, Inc. Process for dna integration using rna-guided endonucleases
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
JP2022546577A (ja) * 2019-09-05 2022-11-04 ソレント・セラピューティクス・インコーポレイテッド Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ）

Also Published As

Publication number Publication date
EP3930852A4 (en) 2022-12-28
BR112021016791A2 (pt) 2021-11-16
EP3930852A1 (en) 2022-01-05
SG11202109163YA (en) 2021-09-29
JP7554759B2 (ja) 2024-09-20
MX2021010281A (es) 2021-09-23
CA3130765A1 (en) 2020-09-03
KR20210133261A (ko) 2021-11-05
US20210388097A1 (en) 2021-12-16
CN113874082A (zh) 2021-12-31
JP2022521956A (ja) 2022-04-13
IL285813A (en) 2021-10-31
CN113874082B (zh) 2024-12-06
WO2020176549A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
JP7554759B2 (ja) Ｂｃｍａに結合する抗原結合性タンパク質
US20250084163A1 (en) Antigen Binding Proteins That Bind ROR1
US20220144966A1 (en) Engineered Variant Antibodies that Bind CD38
JP2024036508A (ja) Ｃｄ３８に結合するバリアント抗体
US20230235059A1 (en) Anti-pd1 antibodies and uses thereof
US20230147852A1 (en) Engineered Antibodies That Bind LAG3
HK40064182A (en) Antigen binding proteins that bind bcma

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VIVASOR, INC.

Free format text: FORMER APPLICANT(S): SORRENTO THERAPEUTICS, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application